Drugs / JNJ-47910382
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01651767 | Aug 2012 → Jun 2013 | chronic hepatitis C virus infection | Janssen R&D Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT01662661 | Jul → Aug 2012 | — | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01586325 | May 2012 → Apr 2014 | chronic hepatitis C virus infection | Janssen R&D Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT01482611 | Nov 2011 → Apr 2012 | hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-47910382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651767 ↗ |
| Action | Inhibit | “is an inhibitor of the reproduction machinery of the Hepatitis C virus (HCV).” NCT01482611 ↗ |
| Route | Oral | “route = oral use.” NCT01482611 ↗ |